PROKARYOTES



Draft Genome Sequence of *Brevibacillus laterosporus* OSY-I₁, a Strain That Produces Brevibacillin, Which Combats Drug-Resistant Gram-Positive Bacteria

Xu Yang,^a [©]En Huang,^b Mustafa Yesil,^a Lingzi Xiaoli,^c Edward G. Dudley,^c Ahmed E. Yousef^{a,d}

Department of Food Science and Technology, The Ohio State University, Columbus, Ohio, USA^a; Department of Environmental and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA^b; Department of Food Science, The Pennsylvania State University, University Park, Pennsylvania, USA^c; Department of Microbiology, The Ohio State University, Columbus, Ohio, USA^d

ABSTRACT Brevibacillus laterosporus $OSY-I_1$ is a Gram-positive spore-forming bacterium isolated from soil. The bacterium produces brevibacillin, an antimicrobial lipopeptide effective against several drug-resistant Gram-positive bacteria. Here, we present the draft genome sequence of the strain $OSY-I_1$ and the gene cluster responsible for the biosynthesis of brevibacillin.

The need for new antimicrobial compounds that are effective against antibioticresistant pathogens is on the rise. According to the U.S. Centers for Disease Control and Prevention (CDC), more than two million people suffered from antibiotic-resistant bacteria with 23,000 annual deaths, and these estimates did not even include people who died from other diseases that were complicated by antibiotic-resistant bacterial infections (1). Brevibacillin, an antimicrobial lipopeptide effective against multidrugresistant strains, was discovered in 2016, and its structure was fully elucidated (2). The compound was isolated from a soil microorganism, *Brevibacillus laterosporus* OSY-I₁, which is a Gram-positive spore-forming bacterium. Based on a follow-up study (3), brevibacillin binds to lipoteichoic acid of the Gram-positive cell wall and further exerts its membrane disruption functions to cause cell leakage. To better understand the biosynthetic pathway of brevibacillin, the draft genome sequence of *B. laterosporus* OSY-I₁ was determined.

The genomic DNA of OSY-I₁ was prepared using the DNeasy blood and tissue kit (Qiagen, Valencia, CA). Concentration of extracted DNA was determined by NanoDrop spectrophotometer (ND-1000; Thermo, Fisher Scientific, MA). The Illumina Nextera v2 kit was used to construct the paired-end library for OSY-I₁, followed by the Illumina Miseq next-generation sequencer (500-cycle) to generate 2×250 bp paired-end reads. The raw reads were later de novo assembled by SPAdes genome assembler (v3.10.1) (4), which generated 173 contigs, with a maximum contig size of 558,482 bp. The resulting draft genome, based on assembled contig information, revealed a genome size of 5,176,419 bp, and an average G+C content of 40.27%, calculated by Artemis software (5). Annotation of the draft genome was performed by the Rapid Annotations using Subsystems Technology (RAST) server (6). Annotation results revealed 4,823 coding sequences (CDS) in the draft genome, with putative functions assigned to 68% CDS. The OSY-I₁ chromosome also contains 111 tRNA genes and one transfer-messenger RNA (tmRNA) gene, as predicted by software Aragon (7), and carries 2 vancomycinresistant operon genes which may synthesize peptidoglycan with altered structure (8). However, OSY-I₁ tested sensitive to vancomycin (MIC 1 μ g/ml), indicating both antibiotic-resistant operons may be dysfunctional (9).

Received 31 August 2017 Accepted 1 September 2017 Published 12 October 2017

Citation Yang X, Huang E, Yesil M, Xiaoli L, Dudley EG, Yousef AE. 2017. Draft genome sequence of *Brevibacillus laterosporus* OSY-I₁, a strain that produces brevibacillin, which combats drug-resistant Gram-positive bacteria. Genome Announc 5:e01093-17. https://doi .org/10.1128/genomeA.01093-17.

Copyright © 2017 Yang et al. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Ahmed E. Yousef, yousef.1@osu.edu.

The average nucleotide identity (ANI) values between OSY-I₁ and four sequenced *B. laterosporus* genomes were calculated using JSpecies software (10). Results indicated that OSY-I₁ shared highest (89.34%) similarity with *B. laterosporus* B9, followed by *B. laterosporus* PE36 (89%), *B. laterosporus* LMG 15441 (88.96%), and *B. laterosporus* GI-9 (88%).

The gene cluster responsible for brevibacillin biosynthesis was identified from the draft genome sequence of $OSY-I_1$. Most of the biosynthetic gene cluster was encoded on three contigs, and gaps were filled by PCR and Sanger sequencing. The complete brevibacillin gene cluster consisted of five nonribosomal peptide synthetases and an ABC transporter. In addition, a complete tyrocidine A gene cluster was discovered, indicating that $OSY-I_1$ is capable of producing multiple antimicrobial compounds.

Accession number(s). The draft genome sequences of *Brevibacillus laterosporus* OSY-I₁ and the brevibacillin biosynthetic gene cluster have been deposited at the NCBI GenBank database under accession numbers NOLX0000000 and MF526970, respectively. The versions described in this paper are NOLX01000000 and MF526970.1, respectively.

ACKNOWLEDGMENTS

We thank the Center for Advanced Processing and Packaging Studies (CAPPS) for partially funding this research and Oak Ridge Institute for Science and Education (ORISE) for providing funding for Lingzi Xiaoli.

REFERENCES

- Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA.
- Yang X, Huang E, Yuan C, Zhang L, Yousef AE. 2016. Isolation and structural elucidation of brevibacillin, an antimicrobial lipopeptide from *Brevibacillus laterosporus* that combats drug-resistant Gram-positive bacteria. Appl Environ Microbiol 82:2763–2772. https://doi.org/10.1128/ AEM.00315-16.
- Yang X, Huang E, Yousef AE. 2017. Brevibacillin, a cationic lipopeptide that binds to lipoteichoic acid and subsequently disrupts cytoplasmic membrane of *Staphylococcus aureus*. Microbiol Res 195:18–23. https:// doi.org/10.1016/j.micres.2016.11.002.
- Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single cell sequencing. J Comput Biol 19:455–477. https://doi.org/10.1089/cmb.2012.0021.
- Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, Rajandream MA, Barrell B. 2000. Artemis: sequence visualization and annotation. Bioinformatics 16:944–945. https://doi.org/10.1093/bioinformatics/16.10.944.

- Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST server: Rapid Annotations using Subsystems Technology. BMC Genomics 9:75. https://doi.org/10.1186/1471-2164-9-75.
- Laslett D, Canback B. 2004. ARAGORN, a program for the detection of transfer RNA genes and transfer-messenger RNA genes in nucleotide sequences. Nucleic Acids Res 32:11–16. https://doi.org/10.1093/nar/ gkh152.
- Liu B, Pop M. 2009. ARDB—antibiotic resistance genes database. Nucleic Acids Res 37:D443–D447. https://doi.org/10.1093/nar/gkn656.
- Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial disc susceptibility tests; approved standard. CLSI document m02-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
- Richter M, Rosselló-Móra R. 2009. Shifting the genomic gold standard for the prokaryotic species definition. Proc Natl Acad Sci U S A 106: 19126–19131. https://doi.org/10.1073/pnas.0906412106.